Noriyuki Enomoto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8706792/publications.pdf

Version: 2024-02-01

		147801]	155660	
157	4,050	31		55	
papers	citations	h-index		g-index	
			ľ		
169	169	169		3569	
107	107	107		3307	
all docs	docs citations	times ranked		citing authors	

#	Article	IF	CITATIONS
1	Possible therapeutic effect of direct haemoperfusion with a polymyxin B immobilized fibre column (PMXâ€DHP) on pulmonary oxygenation in acute exacerbations of interstitial pneumonia. Respirology, 2008, 13, 452-460.	2.3	570
2	Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. Respiratory Medicine, 2009, 103, 846-853.	2.9	202
3	Prognostic Factors for Myositis-Associated Interstitial Lung Disease. PLoS ONE, 2014, 9, e98824.	2.5	131
4	Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease. Respiratory Medicine, 2016, 121, 91-99.	2.9	121
5	The Multicenter Study of a New Assay for Simultaneous Detection of Multiple Anti-Aminoacyl-tRNA Synthetases in Myositis and Interstitial Pneumonia. PLoS ONE, 2014, 9, e85062.	2.5	104
6	Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. Journal of Rheumatology, 2005, 32, 58-64.	2.0	95
7	Clinical diagnosis of idiopathic pleuroparenchymal fibroelastosis: A retrospective multicenter study. Respiratory Medicine, 2017, 133, 1-5.	2.9	89
8	Quantitative Analysis of Fibroblastic Foci in Usual Interstitial Pneumonia. Chest, 2006, 130, 22-29.	0.8	87
9	Idiopathic pleuroparenchymal fibroelastosis: consideration of a clinicopathological entity in a series of Japanese patients. BMC Pulmonary Medicine, 2012, 12, 72.	2.0	81
10	Prognostic Significance of Anti-Aminoacyl-tRNA Synthetase Antibodies in Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease: A Retrospective Case Control Study. PLoS ONE, 2015, 10, e0120313.	2.5	74
11	Treatment of acute exacerbation of idiopathic pulmonary fibrosis with direct hemoperfusion using a polymyxin B-immobilized fiber column improves survival. BMC Pulmonary Medicine, 2015, 15, 15.	2.0	66
12	Distinct profile and prognostic impact of body composition changes in idiopathic pulmonary fibrosis and idiopathic pleuroparenchymal fibroelastosis. Scientific Reports, 2018, 8, 14074.	3.3	66
13	Usual Interstitial Pneumonia Preceding Collagen Vascular Disease: A Retrospective Case Control Study of Patients Initially Diagnosed with Idiopathic Pulmonary Fibrosis. PLoS ONE, 2014, 9, e94775.	2.5	61
14	Radiologic pleuroparenchymal fibroelastosis-like lesion in connective tissue disease-related interstitial lung disease. PLoS ONE, 2017, 12, e0180283.	2.5	60
15	Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD. Rheumatology, 2019, 58, 2143-2152.	1.9	56
16	Nationwide cloud-based integrated database of idiopathic interstitial pneumonias for multidisciplinary discussion. European Respiratory Journal, 2019, 53, 1802243.	6.7	56
17	Distinct prognosis of idiopathic nonspecific interstitial pneumonia (NSIP) fulfilling criteria for undifferentiated connective tissue disease (UCTD). Respiratory Medicine, 2010, 104, 1527-1534.	2.9	52
18	Macrophage mannose receptor, CD206, predict prognosis in patients with pulmonary tuberculosis. Scientific Reports, 2018, 8, 13129.	3.3	50

#	Article	IF	CITATIONS
19	Amount of elastic fibers predicts prognosis ofÂidiopathic pulmonary fibrosis. Respiratory Medicine, 2013, 107, 1608-1616.	2.9	49
20	Clinical significance of myeloperoxidase-anti-neutrophil cytoplasmic antibody in idiopathic interstitial pneumonias. PLoS ONE, 2018, 13, e0199659.	2.5	47
21	Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease. Arthritis Research and Therapy, 2017, 19, 9.	3.5	46
22	Assessment of Immune-Related Interstitial Lung Disease in Patients With NSCLC Treated with Immune Checkpoint Inhibitors: A Multicenter Prospective Study. Journal of Thoracic Oncology, 2020, 15, 1317-1327.	1.1	46
23	Distinctive characteristics and prognostic significance of interstitial pneumonia with autoimmune features in patients with chronic fibrosing interstitial pneumonia. Respiratory Medicine, 2018, 137, 167-175.	2.9	45
24	2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. Respiratory Investigation, 2021, 59, 709-740.	1.8	45
25	Predictive factors for long-term outcome in polymyositis/dermatomyositis-associated interstitial lung diseases. Respiratory Investigation, 2017, 55, 130-137.	1.8	37
26	Clinical Utility of YKL-40 in Polymyositis/dermatomyositis-associated Interstitial Lung Disease. Journal of Rheumatology, 2017, 44, 1394-1401.	2.0	37
27	LTBP2 is secreted from lung myofibroblasts and is a potential biomarker for idiopathic pulmonary fibrosis. Clinical Science, 2018, 132, 1565-1580.	4.3	37
28	Quantitative analysis of lung elastic fibers in idiopathic pleuroparenchymal fibroelastosis (IPPFE): comparison of clinical, radiological, and pathological findings with those of idiopathic pulmonary fibrosis (IPF). BMC Pulmonary Medicine, 2014, 14, 91.	2.0	36
29	Japanese herbal medicine-induced pneumonitis: A review of 73 patients. Respiratory Investigation, 2017, 55, 138-144.	1.8	35
30	The prognostic significance of pneumothorax in patients with idiopathic pulmonary fibrosis. Respirology, 2018, 23, 519-525.	2.3	35
31	Clinical Implication of Proteinase-3-antineutrophil Cytoplasmic Antibody in Patients with Idiopathic Interstitial Pneumonias. Lung, 2016, 194, 235-242.	3.3	33
32	Efficacy of short-term prednisolone treatment in patients with chronic eosinophilic pneumonia. European Respiratory Journal, 2015, 45, 1624-1631.	6.7	32
33	Nonspecific interstitial pneumonia preceding diagnosis of collagen vascular disease. Respiratory Medicine, 2016, 117, 40-47.	2.9	32
34	Prognostic evaluation of serum ferritin in acute exacerbation of idiopathic pulmonary fibrosis. Clinical Respiratory Journal, 2018, 12, 2378-2389.	1.6	31
35	Respiratory impedance is correlated with morphological changes in the lungs on three-dimensional CT in patients with COPD. Scientific Reports, 2017, 7, 41709.	3.3	30
36	Changes in pulmonary endothelial cell properties during bleomycin-induced pulmonary fibrosis. Respiratory Research, 2018, 19, 127.	3.6	30

3

#	Article	IF	CITATIONS
37	Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer. European Journal of Cancer, 2016, 58, 30-37.	2.8	29
38	Analysis of systemic lupus erythematosus-related interstitial pneumonia: a retrospective multicentre study. Scientific Reports, 2019, 9, 7355.	3.3	28
39	Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody–positive Dermatomyositis-associated Interstitial Lung Disease. Journal of Rheumatology, 2019, 46, 935-942.	2.0	28
40	Macrophage Mannose Receptor CD206 Predicts Prognosis in Community-acquired Pneumonia. Scientific Reports, 2019, 9, 18750.	3.3	28
41	Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer. Lung Cancer, 2015, 90, 410-416.	2.0	27
42	Body sizeâ€adjusted dose analysis of pirfenidone in patients with interstitial pneumonia. Respirology, 2018, 23, 318-324.	2.3	27
43	Physiological and morphological differences of airways between COPD and asthma–COPD overlap. Scientific Reports, 2019, 9, 7818.	3.3	27
44	Increased levels of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in idiopathic pulmonary fibrosis. Respiratory Medicine, 2016, 115, 46-52.	2.9	26
45	Evaluation of Programmed Death Ligand 1 (<i>PD-L1</i>) Gene Amplification and Response to Nivolumab Monotherapy in Non–small Cell Lung Cancer. JAMA Network Open, 2020, 3, e2011818.	5.9	26
46	Evaluation of Different Perfusion Durations in Direct Hemoperfusion with Polymyxin B-Immobilized Fiber Column Therapy for Acute Exacerbation of Interstitial Pneumonias. Blood Purification, 2011, 32, 75-81.	1.8	25
47	Relationship between fraction of exhaled nitric oxide and airway morphology assessed by three-dimensional CT analysis in asthma. Scientific Reports, 2017, 7, 10187.	3.3	25
48	IL-17A Attenuates IFN-λ Expression by Inducing Suppressor of Cytokine Signaling Expression in Airway Epithelium. Journal of Immunology, 2018, 201, 2392-2402.	0.8	25
49	Efficacy of corticosteroid and intravenous cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis: A propensity scoreâ€matched analysis. Respirology, 2019, 24, 792-798.	2.3	25
50	Differences in clinical features of acute exacerbation between connective tissue disease-associated interstitial pneumonia and idiopathic pulmonary fibrosis. Chronic Respiratory Disease, 2019, 16, 147997231880947.	2.4	25
51	Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis/dermatomyositisâ€associated <scp>ILD</scp> : A randomized, openâ€label trial. Respirology, 2021, 26, 370-377.	2.3	24
52	Cause of mortality and sarcopenia in patients with idiopathic pulmonary fibrosis receiving <scp>antifibrotic</scp> therapy. Respirology, 2021, 26, 171-179.	2.3	24
53	Disease course and prognosis of pleuroparenchymal fibroelastosis compared with idiopathic pulmonary fibrosis. Respiratory Medicine, 2020, 171, 106078.	2.9	23
54	CD248 and integrin alpha-8 are candidate markers for differentiating lung fibroblast subtypes. BMC Pulmonary Medicine, 2020, 20, 21.	2.0	23

#	Article	IF	CITATIONS
55	Prognostic factors for primary Sjögren's syndrome-associated interstitial lung diseases. Respiratory Medicine, 2019, 159, 105811.	2.9	22
56	Clinical significance of serum S100 calciumâ€binding protein A4 in idiopathic pulmonary fibrosis. Respirology, 2020, 25, 743-749.	2.3	22
57	Nontypeable Haemophilus influenzae exploits the interaction between protein-E and vitronectin for the adherence and invasion to bronchial epithelial cells. BMC Microbiology, 2015, 15, 263.	3. 3	20
58	Clinical Significance of Forced Oscillation Technique for Evaluation of Small Airway Disease in Interstitial Lung Diseases. Lung, 2016, 194, 975-983.	3.3	20
59	Analysis of serum adiponectin and leptin in patients with acute exacerbation of idiopathic pulmonary fibrosis. Scientific Reports, 2019, 9, 10484.	3 . 3	20
60	Clinical significance of lower-lobe interstitial lung disease on high-resolution computed tomography in patients with idiopathic pleuroparenchymal fibroelastosis. Respiratory Medicine, 2019, 154, 122-126.	2.9	20
61	Palliative Care for Idiopathic Pulmonary Fibrosis Patients: Pulmonary Physicians' View. Journal of Pain and Symptom Management, 2020, 60, 933-940.	1.2	20
62	Involvement of autophagy in exacerbation of eosinophilic airway inflammation in a murine model of obese asthma. Autophagy, 2022, 18, 2216-2228.	9.1	19
63	Efficacy of Glucocorticoids and Calcineurin Inhibitors for Anti-aminoacyl-tRNA Synthetase Antibody–positive Polymyositis/dermatomyositis–associated Interstitial Lung Disease: A Propensity Score–matched Analysis. Journal of Rheumatology, 2019, 46, 509-517.	2.0	18
64	Clinical Significance of Interstitial Lung Disease and Its Acute Exacerbation in Microscopic Polyangiitis. Chest, 2021, 159, 2334-2345.	0.8	18
65	Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: mortality and its prediction model. Respiratory Research, 2022, 23, 57.	3.6	18
66	Evaluation of urinary desmosines as a noninvasive diagnostic biomarker in patients with idiopathic pleuroparenchymal fibroelastosis (PPFE). Respiratory Medicine, 2017, 123, 63-70.	2.9	17
67	Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting. Cancer Chemotherapy and Pharmacology, 2019, 84, 147-153.	2.3	17
68	Association of the Geriatric Nutritional Risk Index With the Survival of Patients With Non–Small Cell Lung Cancer After Nivolumab Therapy. Journal of Immunotherapy, 2022, 45, 125-131.	2.4	17
69	Persistent impairment on spirometry in chronic eosinophilic pneumonia. Annals of Allergy, Asthma and Immunology, 2017, 119, 422-428.e2.	1.0	16
70	Increased serum cholesterol and long-chain fatty acid levels are associated with the efficacy of nivolumab in patients with non-small cell lung cancer. Cancer Immunology, Immunotherapy, 2022, 71, 203-217.	4.2	16
71	Pneumothorax in Patients with Idiopathic Pleuroparenchymal Fibroelastosis: Incidence, Clinical Features, and Risk Factors. Respiration, 2021, 100, 19-26.	2.6	16
72	Cumulative Incidence and Predictors of Progression in Corticosteroid-Na \tilde{A} -ve Patients with Sarcoidosis. PLoS ONE, 2015, 10, e0143371.	2.5	15

#	Article	IF	CITATIONS
73	Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study. BMC Pulmonary Medicine, 2021, 21, 221.	2.0	15
74	Step-down treatment from medium-dosage of budesonide/formoterol in controlled asthma. Respiratory Medicine, 2016, 119, 1-6.	2.9	14
75	Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy. Respiratory Medicine Case Reports, 2017, 20, 160-163.	0.4	14
76	Influenza A virus enhances ciliary activity and mucociliary clearance via TLR3 in airway epithelium. Respiratory Research, 2020, 21, 282.	3.6	14
77	Pneumothorax in connective tissue disease-associated interstitial lung disease. PLoS ONE, 2020, 15, e0235624.	2.5	14
78	Acute exacerbation of unclassifiable idiopathic interstitial pneumonia: comparison with idiopathic pulmonary fibrosis. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662093577.	2.6	13
79	Conventional type 2 lung dendritic cells are potent inducers of follicular helper T cells in the asthmatic lung. Allergology International, 2021, 70, 351-359.	3.3	13
80	Serum S100A8 and S100A9 as prognostic biomarkers in acute exacerbation of idiopathic pulmonary fibrosis. Respiratory Investigation, 2021, 59, 827-836.	1.8	13
81	Podoplaninâ€positive myofibroblasts: a pathological hallmark of pleuroparenchymal fibroelastosis. Histopathology, 2018, 72, 1209-1215.	2.9	12
82	<p>Effect of PD-1 inhibitor on exhaled nitric oxide and pulmonary function in non-small cell lung cancer patients with and without COPD</p> . International Journal of COPD, 2019, Volume 14, 1867-1877.	2.3	12
83	Prognostic significance of peripheral blood monocyte and neutrophil counts in rheumatoid arthritis-associated interstitial lung disease. Respiratory Medicine, 2021, 182, 106420.	2.9	12
84	Synergistic Proinflammatory Responses by IL-17A and Toll-Like Receptor 3 in Human Airway Epithelial Cells. PLoS ONE, 2015, 10, e0139491.	2.5	12
85	Frequency and clinical relevance of anti-cyclic citrullinated peptide antibody in idiopathic interstitial pneumonias. Respiratory Medicine, 2019, 154, 102-108.	2.9	11
86	Quality of dying and death in patients with interstitial lung disease compared with lung cancer: an observational study. Thorax, 2021, 76, 248-255.	5.6	11
87	Subcutaneous injection of interferon gamma therapy could be useful for anti–IFN-γ autoantibody associated disseminated nontuberculous mycobacterial infection. Journal of Infection and Chemotherapy, 2021, 27, 373-378.	1.7	11
88	Gremlin-1 for the Differential Diagnosis of Idiopathic Pulmonary Fibrosis Versus Other Interstitial Lung Diseases: A Clinical and Pathophysiological Analysis. Lung, 2021, 199, 289-298.	3.3	11
89	Prognostic and Clinical Value of Cluster Analysis in Idiopathic Pleuroparenchymal Fibroelastosis Phenotypes. Journal of Clinical Medicine, 2021, 10, 1498.	2.4	11
90	Radiological pleuroparenchymal fibroelastosis-like lesion in idiopathic interstitial pneumonias. Respiratory Research, 2021, 22, 290.	3.6	11

#	Article	IF	Citations
91	Plasma connective tissue growth factor levels as potential biomarkers of airway obstruction in patients with asthma. Annals of Allergy, Asthma and Immunology, 2014, 113, 295-300.	1.0	10
92	Impact of angiopoietin-1 and -2 on clinical course of idiopathic pulmonary fibrosis. Respiratory Medicine, 2016, 114, 18-26.	2.9	10
93	Differences in airway structural changes assessed by 3-dimensional computed tomography in asthma and asthma–chronic obstructive pulmonary disease overlap. Annals of Allergy, Asthma and Immunology, 2018, 121, 704-710.e1.	1.0	10
94	Immunization with dendritic cells loaded with α-galactosylceramide at priming phase, but not at boosting phase, enhances cytotoxic T lymphocyte activity against infection by intracellular bacteria. FEMS Immunology and Medical Microbiology, 2007, 51, 350-362.	2.7	9
95	Effects of indacaterol versus tiotropium on respiratory mechanics assessed by the forced oscillation technique in patients with chronic obstructive pulmonary disease. International Journal of COPD, 2015, 10, 1139.	2.3	9
96	Body composition changes successfully classify prognosis in patients with mycobacterium avium complex lung disease. Journal of Infection, 2019, 79, 341-348.	3.3	9
97	Clinical, radiological, and pathological evaluation of "NSIP with OP overlap―pattern compared with NSIP in patients with idiopathic interstitial pneumonias. Respiratory Medicine, 2020, 174, 106201.	2.9	9
98	Prognostic classification in acute exacerbation of idiopathic pulmonary fibrosis: a multicentre retrospective cohort study. Scientific Reports, 2021, 11, 9120.	3.3	9
99	Prospective nationwide multicentre cohort study of the clinical significance of autoimmune features in idiopathic interstitial pneumonias. Thorax, 2022, 77, 143-153.	5.6	9
100	Impact of antifibrotic therapy on lung cancer development in idiopathic pulmonary fibrosis. Thorax, 2022, 77, 727-730.	5 . 6	9
101	Association of the Geriatric Nutritional Risk Index with the survival of patients with non-small-cell lung cancer after platinum-based chemotherapy. BMC Pulmonary Medicine, 2021, 21, 409.	2.0	9
102	Idiopathic pleuroparenchymal fibroelastosis: three-dimensional computed tomography assessment of upper-lobe lung volume. European Respiratory Journal, 2022, 60, 2200637.	6.7	9
103	Continuation maintenance therapy with S-1 in chemotherapy-na \tilde{A} -ve patients with advanced squamous cell lung cancer. Investigational New Drugs, 2016, 34, 490-496.	2.6	8
104	Simultaneous Occurrence of Sarcoidosis and Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis in a Patient with Lung Cancer. Internal Medicine, 2019, 58, 3299-3304.	0.7	8
105	Correlation of the modified Medical Research Council dyspnea scale with airway structure assessed by three-dimensional CT in patients with chronic obstructive pulmonary disease. Respiratory Medicine, 2019, 146, 76-80.	2.9	8
106	Clinical Outcomes of Anti-programmed Death-1 Antibody–Related Pneumonitis in Patients with Non-Small Cell Lung Cancer. SN Comprehensive Clinical Medicine, 2020, 2, 570-578.	0.6	8
107	Individual psychotherapy using psychological first aid for frontline nurses at high risk of psychological distress during the <scp>COVID</scp> â€19 pandemic. Psychiatry and Clinical Neurosciences, 2021, 75, 25-27.	1.8	8
108	An exploratory trial of intravenous immunoglobulin therapy for idiopathic pulmonary fibrosis: a preliminary multicenter report. Clinical Respiratory Journal, 2016, 10, 746-755.	1.6	7

#	Article	IF	CITATIONS
109	Utility of serum Aspergillus-galactomannan antigen to evaluate the risk of severe acute exacerbation in chronic obstructive pulmonary disease. PLoS ONE, 2018, 13, e0198479.	2.5	7
110	<p>Once-daily fluticasone furoate/vilanterol combination versus twice-daily budesonide/formoterol combination in the treatment of controlled stable asthma: a randomized crossover trial</p> . Journal of Asthma and Allergy, 2019, Volume 12, 253-261.	3.4	7
111	Prognostic impact of an early marginal decline in forced vital capacity in idiopathic pulmonary fibrosis patients treated with pirfenidone. Respiratory Investigation, 2019, 57, 552-560.	1.8	7
112	Clinical Significance of Cold-Inducible RNA-Binding Protein in Idiopathic Pulmonary Fibrosis. Chest, 2021, 160, 2149-2157.	0.8	7
113	A case of treatment with voriconazole for chronic progressive pulmonary aspergillosis in a patient receiving tacrolimus for dermatomyositis-associated interstitial lung disease. Respiratory Medicine Case Reports, 2015, 16, 163-165.	0.4	6
114	Prophylactic aprepitant is better than salvage for carboplatin-based chemotherapy: a propensity score-matched analysis. Medical Oncology, 2018, 35, 139.	2.5	6
115	Predictors of acute exacerbation in biopsy-proven idiopathic pulmonary fibrosis. Respiratory Investigation, 2020, 58, 177-184.	1.8	6
116	Intravoxel incoherent motion magnetic resonance imaging for predicting the long-term efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer. Lung Cancer, 2020, 143, 47-54.	2.0	6
117	Soluble hemoglobin scavenger receptor CD163 (sCD163) predicts mortality of community-acquired pneumonia. Journal of Infection, 2016, 73, 375-377.	3.3	5
118	Neutrophil gelatinase-associated lipocalin in patients with sarcoidosis. Respiratory Medicine, 2018, 138, S20-S23.	2.9	5
119	Synchronous Occurrence of Bazex Syndrome and Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome in a Patient with Lung Cancer. Internal Medicine, 2019, 58, 3267-3271.	0.7	5
120	Pulse oximetric saturation to fraction of inspired oxygen (SpO ₂ /FIO ₂) ratio 24 hours after high-flow nasal cannula (HFNC) initiation is a good predictor of HFNC therapy in patients with acute exacerbation of interstitial lung disease. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662090632.	2.6	5
121	Predictors for bronchoalveolar lavage recovery failure in diffuse parenchymal lung disease. Scientific Reports, 2021, 11, 1682.	3.3	5
122	Comparative assessment of NOIR-SS and ddPCR for ctDNA detection of EGFR L858R mutations in advanced L858R-positive lung adenocarcinomas. Scientific Reports, 2021, 11, 14999.	3.3	5
123	IgG4-related disease presenting with combined pulmonary fibrosis and emphysema (CPFE). Respiratory Medicine Case Reports, 2018, 25, 257-260.	0.4	4
124	Clinical features of three-dimensional computed tomography-based radiologic phenotypes of chronic obstructive pulmonary disease. International Journal of COPD, 2019, Volume 14, 1333-1342.	2.3	4
125	Erlotinib and bevacizumab in elderly patients ≥75Âyears old with non-small cell lung cancer harboring epidermal growth factor receptor mutations. Investigational New Drugs, 2021, 39, 210-216.	2.6	4
126	Cluster analysis-based clinical phenotypes of idiopathic interstitial pneumonias: associations with acute exacerbation and overall survival. BMC Pulmonary Medicine, 2021, 21, 63.	2.0	4

#	Article	IF	CITATIONS
127	Diagnostic and prognostic significance of serum angiopoietin-1 and -2 concentrations in patients with pulmonary hypertension. Scientific Reports, 2021, 11, 15502.	3.3	4
128	Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis. Scientific Reports, 2021, 11, 18579.	3.3	4
129	MET Amplification and Efficacy of Nivolumab in Patients With NSCLC. JTO Clinical and Research Reports, 2021, 2, 100239.	1.1	4
130	Standardised 3D-CT lung volumes for patients with idiopathic pulmonary fibrosis. Respiratory Research, 2022, 23, .	3.6	4
131	Simultaneous reactivation of cytomegalovirus in an adult patient with varicella. Journal of Dermatology, 2015, 42, 658-659.	1.2	3
132	A case of spontaneous regression of pulmonary mucosa-associated lymphoid tissue (MALT) type lymphoma with Sjã¶gren's syndrome treated with methotrexate for rheumatoid arthritis. Respiratory Medicine Case Reports, 2015, 15, 4-6.	0.4	3
133	Synchronous Duodenal Cancer and Lung Cancer Harboring an Epidermal Growth Factor Receptor Mutation Treated with Erlotinib and Oral Fluoropyrimidine. Internal Medicine, 2017, 56, 2367-2371.	0.7	3
134	An Acquired Epidermal Growth Factor Receptor T790M Mutation after the Addition of Bevacizumab to Preceding Erlotinib Monotherapy in a Lung Cancer Patient with Leptomeningeal Metastases. Internal Medicine, 2018, 57, 3423-3427.	0.7	3
135	Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study. Medical Oncology, 2018, 35, 108.	2.5	3
136	Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma. Investigational New Drugs, 2019, 37, 531-537.	2.6	3
137	Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662095378.	2.6	3
138	Sarcoid-like Granulomatous Lung Disease with Subacute Progression in Silicosis. Internal Medicine, 2022, 61, 395-400.	0.7	3
139	Transient leukocytopenia following combination therapy for COVID-19. Respiratory Investigation, 2021, 60, 158-158.	1.8	3
140	Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report. JTO Clinical and Research Reports, 2022, 3, 100263.	1.1	3
141	Effects of long-acting muscarinic antagonists on promoting ciliary function in airway epithelium. BMC Pulmonary Medicine, 2022, 22, 186.	2.0	3
142	Changes in cross-sectional area of pulmonary vessels on chest computed tomography after chemotherapy in patients with advanced non-squamous non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology, 2016, 77, 1011-1018.	2.3	2
143	Kessler Psychological Distress (K6) Questionnaire Scores Can Predict Autistic Traits and the Current and Prospective Suicidal Ideation in Medical University Students: A Prospective Study. SAGE Open, 2021, 11, 215824402199459.	1.7	2
144	Simple method for detecting idiopathic interstitial pneumonias by measuring vertical lung length on chest X-ray. Scientific Reports, 2021, 11, 7669.	3.3	2

#	Article	IF	CITATIONS
145	Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with uncommon histology: a propensity-score-matched analysis. BMC Pulmonary Medicine, 2021, 21, 309.	2.0	2
146	Impact of end-of-life respiratory modalities on quality of dying and death and symptom relief in patients with interstitial lung disease: a multicenter descriptive cross-sectional study. Respiratory Research, 2022, 23, 79.	3.6	2
147	Chemotherapy for patients with advanced lung cancer with interstitial lung disease: a prospective observational study. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232211083.	2.5	2
148	Sequential addition of aprepitant in patients receiving carboplatin-based chemotherapy. Medical Oncology, 2016, 33, 65.	2.5	1
149	Development of a novel T cellâ€oriented vaccine using CTL/Thâ€hybrid epitope long peptide and biodegradable microparticles, against an intracellular bacterium. Microbiology and Immunology, 2020, 64, 666-678.	1.4	1
150	Prophylactic granulocyte-colony stimulating factor in patients with lung neuroendocrine carcinoma receiving platinum agents plus etoposide. Cancer Treatment and Research Communications, 2021, 29, 100493.	1.7	1
151	EGFR-Mutated Lung Adenocarcinoma Successfully Treated With Osimertinib After Spontaneous Transformation to SCLC and Adenocarcinoma With Neuroendocrine Differentiation: Case Report. JTO Clinical and Research Reports, 2022, 3, 100264.	1.1	1
152	Trimethoprim-sulfamethoxazole induced eosinophilic pneumonia: A case report. Respiratory Medicine Case Reports, 2022, 37, 101632.	0.4	1
153	Multiple organ infarction caused by aortic thrombus in a lung cancer patient with the BRAF mutation. Respiratory Medicine Case Reports, 2022, 36, 101608.	0.4	1
154	Low-dose Fluticasone Propionate in Combination With Salmeterol in Patients With Chronic Obstructive Pulmonary Disease. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2018, 12, 117954841877170.	0.9	0
155	Paraneoplastic Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome Should Be Treated with Low-dose Prednisolone During Pembrolizumab Therapy: The Authors' Reply. Internal Medicine, 2020, 59, 599-599.	0.7	0
156	Longitudinal lung involvement of systemic lupus erythematosusâ€related vasculitis and alveolar proteinosisâ€like reaction. Respirology Case Reports, 2020, 8, e00559.	0.6	0
157	Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy in non-squamous non-small-cell lung cancer Journal of Clinical Oncology, 2016, 34, e20504-e20504.	1.6	O